Hepatocellular carcinoma: pilot trial of treatment with Y-90 microspheres.
The potential use of yttrium-90 glass microspheres in the treatment of hepatocellular carcinoma was assessed in a pilot study of seven patients. The Y-90 microspheres were injected via a hepatic artery catheter. In this group of patients, no toxicity was observed for absorbed doses of between 5,000 and 10,000 cGy to the liver and up to 32,000 cGy to the tumor itself. Tumor response was seen only at the higher absorbed doses. The new Y-90 glass microspheres can safely deliver large doses of internal radiation to hepatic tumors as long as extrahepatic shunting can be excluded. Extrahepatic shunting will be the main limitation to this form of radiation therapy.
Houle
S
S
Department of Radiology, Toronto General Hospital, Ont, Canada.
Yip
T K
TK
Shepherd
F A
FA
Rotstein
L E
LE
Sniderman
K W
KW
Theis
E
E
Cawthorn
R H
RH
Richmond-Cox
K
K
D001918:Brachytherapy / Q000379:methods*; D006528:Carcinoma, Hepatocellular / Q000532:radiotherapy*; D004307:Dose-Response Relationship, Radiation; D005898:Glass; D006499:Hepatic Artery; D006801:Humans; D008113:Liver Neoplasms / Q000532:radiotherapy*; D008863:Microspheres; D010865:Pilot Projects; D015021:Yttrium Radioisotopes / Q000627:therapeutic use*
D015021:Yttrium Radioisotopes